Cantargia is developing antibodies against IL1RAP. Data from its Phase IIa CANFOUR trial, investigating nadunolimab in first-line non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), support the hypothesis that nadunolimab has a synergistic benefit with chemotherapy. At the ASCO Annual Meeting in June, Cantargia presented promising interim results for nadunolimab from a Phase I/IIa in PDAC and a Phase IIa trial in NSCLC.

The company is now preparing for the Phase II/III trial in metastatic PDAC in collaboration with PanCAN. A second programme, CAN10, is being developed for treatment of myocarditis and systemic sclerosis. New supportive preclinical data were recently presented and Phase I clinical trials are planned for early 2023. Nadunolimab is being investigated across eight different cancers in different combinations. Cantargia had a cash and short-term investment position of SEK496.5m at end-Q322.